Russian-developed COVID-19 vaccine 95% effective... under $20

Russian President Vladimir Putin (Photo by Yonhap News)

[Asia Economy Reporter Moon Jiwon] Research results have shown that the immunity effectiveness of Sputnik V, a novel coronavirus (COVID-19) vaccine developed by Russia, reaches 95%.

On the 24th (local time), according to AFP, the Gamaleya National Research Center for Epidemiology and Microbiology under the Russian Ministry of Health, which developed Sputnik V, released a statement announcing the interim results of the second phase analysis of the vaccine.

The Gamaleya National Research Center for Epidemiology and Microbiology explained that this research result was obtained 42 days after the first dose of the vaccine.

However, AFP reported that the number of subjects tested was not disclosed.

Major foreign media quoted a statement released through Sputnik V's official Twitter, stating that the international price of Sputnik V, which requires two doses, will be under $20 (approximately 23,000 KRW).

The statement explained that the vaccine is in a freeze-dried form and can be stored at 2 to 8 degrees Celsius.

The statement also mentioned that the vaccine is scheduled to be produced in India, Brazil, China, and Korea, and could be supplied to the international market around January next year.

This content was produced with the assistance of AI translation services.